Piscataway, NJ, July 19, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Oral Solution to its product line.
Gabapentin Oral Solution is indicated for:
-
-
- Postherpetic Neuralgia in adults
- Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy
-
Gabapentin Oral Solution is available in the strengths of 250 mg per 5 mL in a 470 mL count size bottle.
To learn more about Gabapentin Oral Solution, please visit https://www.camberpharma.com/gabapentinoralsolution
